ライフサイエンスコーパス: continue

1 in 2015, but its use in other countries may continue.

2 from the initial registry to the subsequent continued access registry, both at 30 days (8.2% vs. 0.7

3 While forest loss and fire continued after RSPO certification, certified palm oil w

4 lizumab after long-term treatment results in continued benefit, as evidenced by improved symptom cont

5 mice enabling longitudinal TFAR profiling by continued bioimaging throughout the lives of the animals

6 ot having sex on first meeting, while living/continued communication with sexual partner(s) was assoc

7 A continued excess mortality occurred after perforation, w

8 n the protein reach the transition state and continue folding.

9 Continued follow-up is warranted.

10 c plugged catheter, antibiotic treatment was continued for 7 days.

11 Genetic diversity is maintained by continuing generation and removal of variants.

12 Continued input of observations into FRED to fill gaps i

13 ely limit the ability of plastic surgeons to continue its use in this clinical context.

14 At 12 weeks, patients continued on anakinra showed an improvement in peak Vo2

15 ified AHC or ovalbumin on alternate days and continued on HFD for another 10 weeks.

16 -threatening form of status epilepticus that continues or recurs despite 24 hours or more of anesthet

17 With an aging ESRD population and continued organ shortage, preservation of average post-t

18 As debates continue over the functional significance of many specif

19 ration was predicted to be more effective if continued over 2 years rather than 1 year, and if done a

20 Continued refinement to the model to reflect diverse bio

21 g those made in recent decades, will require continued research into mechanisms underlying disease pr

22 to switch to the open-label study regimen or continue the control regimen.

23 supplementary immunization activities (SIAs) continued, the targeting of settlements at high risk for

24 ur search for an efficacious malaria vaccine continues, the development of a whole-organism vaccine i

25 0 mg twice daily) was started on day -10 and continued through day +100 post-HCT.

26 bed appropriately to treat infections, there continue to be a large number of inappropriately prescri

27 chanistic aspects of Fe/S protein biogenesis continue to be elucidated by biochemical and ultrastruct

28 As laser cooling experiments continue to bring massive mechanical systems to unpreced

29 ght technological developments in 2D IR that continue to expand the scope of scientific problems that

30 The crystals then continue to grow to develop morphologies characteristic

31 However, HIV-positive blacks continue to have much higher rates of ESRD than HIV-posi

32 that short- and long-term clinical outcomes continue to improve.

33 horts in diverse environments worldwide will continue to provide critical knowledge about the factors

34 into this interesting set of compounds will continue to provide insights into fundamental questions

35 thods evolve, these new systems of care must continue to serve the needs of children.

36 dent, and thus plants without stomata should continue to take up COS in the dark.

37 t decrease significantly after the tear, but continued to decline compared with control eyes at all e

38 Acute graft-versus-host disease (aGVHD) continues to be a frequent and devastating complication

39 Exposure to violence continues to be a growing epidemic, particularly among c

40 recognized, their exact function in the CNS continues to be explored.

41 lity of radiation dose according to facility continues to be wide.

42 plications of chalcogen-bonding interactions continues to develop, debate still surrounds the energet

43 y removal and conventional immunosuppression continues to provide excellent patient and graft surviva

44 , the total number of children with stunting continues to rise in sub-Saharan Africa.

45 population worldwide, the incidence of falls continues to rise.

46 e goal of creating a more powerful tool that continues to serve the existing community while addressi

47 ised pulmonary exacerbation rate in patients continuing treatment through extension week 96 (0.65, 0.

48 d with vaccinia virus, but mass fluctuations continue until cell death.

49 , membranes heal spontaneously and pregnancy continues until term.

50 nd 4.3 (2.9-7.6) per 100 000 population with continued use of longer therapy-ie, the short-course reg